参考文献/References:
[1] Murphy SP,Ibrahim NE,Januzzi JL Jr. Heart failure with reduced ejection fraction:a review[J]. JAMA,2020,324(5):488-504.
[2] Sridharan S,Kini RM,Richards AM. Venom natriuretic peptides guide the design of heart failure therapeutics[J]. Pharmacol Res,2020,155:104687.
[3] Hunt PJ,Richards AM,Espiner EA,et al. Bioactivity and metabolism of C-type natriuretic peptide in normal man[J]. J Clin Endocrinol Metab,1994,78(6):1428-1435.
[4] Hu P,Zhao XQ,Wang J,et al. Paradoxical expressions of natriuretic peptide receptor-C and neutral endopeptidase account for C-type natriuretic peptide decline during the progression of experimental obstructive nephropathy[J]. J Renin Angiotensin Aldosterone Syst,2014,15(4):458-465.
[5] Goetze JP,Bruneau BG,Ramos HR,et al. Cardiac natriuretic peptides[J]. Nat Rev Cardiol,2020,17(11):698-717.
[6] Ichiki T,Dzhoyashvili N,Burnett JC Jr. Natriuretic peptide based therapeutics for heart failure:cenderitide:a novel first-in-class designer natriuretic peptide[J]. Int J Cardiol,2019,281:166-171.
[7] Moyes AJ,Chu SM,Aubdool AA,et al. C-type natriuretic peptide co-ordinates cardiac structure and function[J]. Eur Heart J,2020,41(9):1006-1020.
[8] Nagai T,Iwakami N,Nakai M,et al. Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure:insight from a nationwide claim-based database[J]. Int J Cardiol,2019,280:104-109.
[9] Kittleson MM. Nesiritide and Me[J]. Circ Heart Fail,2018,11(8):e005440.
[10] Singh A,Laribi S,Teerlink JR,et al. Agents with vasodilator properties in acute heart failure[J]. Eur Heart J,2017,38(5):317-325.
[11] Lisy O,Huntley BK,McCormick DJ,et al. Design,synthesis,and actions of a novel chimeric natriuretic peptide:CD-NP[J]. J Am Coll Cardiol,2008,52(1):60-68.
[12] Lee CY,Huntley BK,McCormick DJ,et al. Cenderitide:structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancingin vivo and ex vivo actions[J]. Eur Heart J Cardiovasc Pharmacother,2016,2(2):98-105.
[13] Ichiki T,Schirger JA,Huntley BK,et al. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system:regulation and therapeutic implications[J]. J Mol Cell Cardiol,2014,75:199-205.
[14] Martínez-Martínez E,Brugnolaro C,Ibarrola J,et al. CT-1(cardiotrophin-1)-Gal-3 (galectin-3) axis in cardiac fibrosis and inflammation[J]. Hypertension,2019,73(3):602-611.
[15] Martin FL,Sangaralingham SJ,Huntley BK,et al. CD-NP:a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart[J]. PLoS One,2012,7(12):e52422.
[16] Dickey DM,Potter LR. Dendroaspis natriuretic peptide and the designer natriuretic peptide,CD-NP,are resistant to proteolytic inactivation[J]. J Mol Cell Cardiol,2011,51(1):67-71.
[17] Munawar A,Ali SA,Akrem A,et al. Snake venom peptides:tools of biodiscovery[J]. Toxins(Basel),2018,10(11):474.
[18] Ng XW,Huang Y,Liu KL,et al. Investigation of cenderitide controlled release platforms for potential local treatment of cardiovascular pathology[J]. J Pharm Sci,2014,103(5):1400-1410.
[19] Ng XW,Huang Y,Chen HH,et al. Cenderitide-eluting film for potential cardiac patch applications[J]. PLoS One,2013,8(7):e68346.
[20] Kawakami R,Lee CYW,Scott C,et al. A human study to evaluate safety,tolerability,and cyclic GMP activating properties of cenderitide in subjects with stable chronic heart failure[J]. Clin Pharmacol Ther,2018,104(3):546-552.
[21] Chen Y,Harty GJ,Huntley BK,et al. CRRL269:a novel designer and renal-enhancing pGC-A peptide activator[J]. Am J Physiol Regul Integr Comp Physiol,2018,314(3):R407-R414.
[22] Chen Y,Harty GJ,Zheng Y,et al. CRRL269:a novel particulate guanylyl cyclase a receptor peptide activator for acute kidney injury[J]. Circ Res,2019,124(10):1462-1472.
[23] Menon A,Hong L,Savio-Galimberti E,et al. Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation[J]. J Mol Cell Cardiol,2019,132:24-35.
[24] McKie PM,Cataliotti A,Huntley BK,et al. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering,renal-enhancing,and aldosterone-suppressing actions[J]. J Am Coll Cardiol,2009,54(11):1024-1032.
[25] Chen Y,Schaefer JJ,Iyer SR,et al. Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP[J]. Am J Physiol Regul Integr Comp Physiol,2020,318(4):R669-R676.
[26] Mckie PM,Cataliotti A,Ichiki T,et al. M-atrial natriuretic peptide and nitroglycerin in a canine model of?experimental acute hypertensive heart failure:differential actions of 2 cGMP activating therapeutics[J]. J Am Heart Assoc,2014,3(1):e000206.
[27] Chen HH,Neutel JM,Smith DH,et al. A first-in-human trial of a novel designer natriuretic peptide ZD100 in human hypertension[J]. J Am Soc Hypertens,2016,10(4):e23.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(9):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(9):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(9):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(9):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(9):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(9):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]彭金华,王平,胡婧,等.左心耳封堵术对非瓣膜性心房颤动患者心脏利尿钠肽分泌功能的影响[J].心血管病学进展,2019,(6):873.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.009]
PENG Jinhua,WANG PingHU Jing,YANG Jingqi,et al.Effect of Left Atrial Appendage Closure on Cardiac Natriuretic Peptide Secretion in Patients with Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(9):873.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.009]
[8]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[9]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(9):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[10]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[11]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(9):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]